Semaglutide
GLP-1 Fat Loss Compound
The compound behind Ozempic/Wegovy. GLP-1 receptor agonist producing significant appetite suppression, fat loss, and metabolic improvement with once-weekly dosing.
Starting From
$79.99
Sold By
Apollo Peptide Sciences
Suggested Protocol
Dose escalation protocol: start at 0.25mg weekly for 4 weeks, increase to 0.5mg, then 1mg, then up to 2.4mg at maintenance. Subcutaneous injection once weekly. Reconstitute with bacteriostatic water. The escalation protocol minimizes GI side effects during adaptation.
14.9%
Body Wt. Loss
~7 days
Half-Life
Once weekly
Dosing
How a Single Weekly Injection Changed the Entire Science of Weight Loss
Semaglutide is the active compound in the pharmaceutical products Ozempic and Wegovy — now widely available as a research peptide through Apollo Peptide Sciences. It is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist with a C18 fatty diacid side chain modification that extends its half-life to approximately 7 days, enabling the once-weekly dosing protocol that defines its clinical use.
The mechanism of action is multi-dimensional. At the hypothalamic level, semaglutide activates GLP-1 receptors in the appetite and satiety centers, producing powerful reductions in hunger signals and food intake — without the stimulant side effects or psychological dependence of traditional appetite suppressants. Simultaneously, it slows gastric emptying (prolonging satiety after meals), reduces glucagon secretion, and improves insulin sensitivity at peripheral tissues.
Clinical data from the STEP trial program demonstrated an average of 14.9% body weight reduction over 68 weeks in research subjects — the most significant weight loss outcomes ever documented for a pharmaceutical compound until the subsequent emergence of dual and triple receptor agonists. For individuals with significant excess body fat, semaglutide produces metabolic improvements (reduced HbA1c, improved lipid profiles, lower blood pressure) that extend well beyond aesthetics.
Apollo Peptide Sciences offers semaglutide in 5mg, 10mg, and 15mg formats. The 5mg vial is the standard entry point for research protocols — ideal for dose escalation and establishing individual tolerance before moving to higher-volume formats.
Three Mechanisms at Once
Appetite Suppression, Gastric Emptying, Insulin Sensitivity — How Each Works
Semaglutide's power comes from hitting three systems simultaneously. In the hypothalamus, GLP-1 receptor activation switches off hunger signals and amplifies satiety — you simply stop feeling driven to eat. In the stomach, it slows gastric emptying, meaning food sits in the stomach longer and the sensation of fullness lasts hours instead of minutes after a meal. In peripheral tissues, it improves insulin sensitivity, reducing the metabolic dysfunction that causes the body to store fat preferentially. No previous weight loss intervention addressed all three mechanisms with a single weekly injection.
The Ozempic Molecule
Same Active Compound as Ozempic and Wegovy — What Changed Is the Format
Semaglutide is the active molecule in Ozempic (diabetes indication) and Wegovy (weight loss indication) — the identical GLP-1 receptor agonist with the same C18 fatty acid modification that extends half-life to approximately 7 days. What Apollo Peptide Sciences provides is the same compound in lyophilized research format, reconstituted with bacteriostatic water. The compound's pharmacology is identical; the difference is the delivery format, the price point, and the absence of the pharmaceutical brand markup that makes prescription Wegovy cost over $1,000/month for many users.
The Escalation Protocol
Why Starting at 0.25mg Is the Difference Between Tolerating Semaglutide and Quitting It
Semaglutide's GI side effects — nausea, reduced appetite, occasional vomiting in the first weeks — are dose-dependent and adaptation-dependent. Researchers who jump straight to therapeutic doses (1mg+) experience the worst GI profile and often discontinue. The escalation protocol (0.25mg → 0.5mg → 1mg → 2.4mg at 4-week intervals) gives the GI tract time to adapt to slowed gastric emptying at each step. By the time you reach 1mg or above, the GI adaptation is largely complete and the dose is well tolerated. Patience during escalation is not a nice-to-have — it determines whether you complete the protocol.
Key Benefits
Average 14.9% body weight reduction demonstrated in clinical research
Powerful appetite suppression via hypothalamic GLP-1 receptor activation
Once-weekly dosing enabled by extended half-life modification
Slows gastric emptying for prolonged satiety after meals
Improves insulin sensitivity and glucose metabolism
Reduces visceral fat preferentially over subcutaneous fat
Improves cardiovascular risk markers — lipids, blood pressure, HbA1c
Available in 5mg, 10mg, and 15mg formats for different research durations
Full Protocol
Dose escalation protocol: start at 0.25mg weekly for 4 weeks, increase to 0.5mg, then 1mg, then up to 2.4mg at maintenance. Subcutaneous injection once weekly. Reconstitute with bacteriostatic water. The escalation protocol minimizes GI side effects during adaptation.
Best Stacked With
More in Weight Management
View All
Semaglutide 10mg
The intermediate format for researchers who have completed the escalation from 5mg and are now in the therapeutic range where meaningful, sustained fat loss occurs.
